ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Cognitive-Behavioural and Hypnotic Treatment of Chronic Primary Insomnia Among the Elderly

This study is ongoing, but not recruiting participants.

Sponsored by: University of Bergen
Information provided by: University of Bergen
ClinicalTrials.gov Identifier: NCT00295386
  Purpose

The present study examines the short- and long-term clinical efficacy of cognitive-behavior therapy and pharmacological treatment in patients suffering from late-life primary insomnia. 46 subjects suffering from chronic primary insomnia were randomized into either cognitive-behavior therapy (CBT, n=18), hypnotics (7.5 mg Zopiclone, n=16), or placebo treatment (n=12). All active treatments lasted 6 weeks with follow-ups conducted at 6 months. Ambulant clinical polysomnography (PSG) and sleep diaries were used on all three assessment points.


Condition Intervention Phase
Insomnia
Behavioral: Cognitive behavior therapy (CBT)
Drug: Zopiclone
Phase IV

Drug Information available for:   Zopiclone   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment

Further study details as provided by University of Bergen:

Study Start Date:   January 2004
Estimated Study Completion Date:   December 2005

  Eligibility
Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • age 55 years or older
  • fulfilment of the DMS-IV criteria for insomnia, including difficulties initiating sleep, maintaining sleep, and/or early morning awakenings with no ability of return to sleep
  • duration of at least 3 months
  • complaints of impaired daytime functioning.

Exclusion Criteria:

  • use of hypnotic medication the last 4 weeks before project start
  • use of antidepressive or antipsychotic medications
  • signs of dementia or other serious cognitive impairment defined by a score under 25 on the Mini-Mental State Examination
  • presence of a major depressive disorder or other severe mental disorder as identified by a clinical assessment based on The Structured Clinical Interview for DSM-IV (SCID-I)
  • presence of sleep apnea defined as (A/H index > 15) or periodic limb movements during sleep (PLM index with arousal > 15),
  • working nightshifts and unable or unwilling to discontinue this work pattern,
  • willingness or inability to stop taking sleep medication before start
  • having a serious somatic conditions preventing further participation
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00295386

Locations
Norway
University of Bergen    
      Bergen, Norway, 5020

Sponsors and Collaborators
University of Bergen

Investigators
Study Director:     Inger H Nordhus, PhD     University of Bergen    
  More Information


Publications of Results:

Study ID Numbers:   REK Vest nr. 186.03
First Received:   February 21, 2006
Last Updated:   July 17, 2006
ClinicalTrials.gov Identifier:   NCT00295386
Health Authority:   Norway: Norwegian Medicines Agency

Study placed in the following topic categories:
Zopiclone

Additional relevant MeSH terms:
Therapeutic Uses
Physiological Effects of Drugs
Hypnotics and Sedatives
Central Nervous System Depressants
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers